Total amount: € 0,00
HOW TO ORDER
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
A Journal on Dermatology and Sexually Transmitted Diseases
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Giornale Italiano di Dermatologia e Venereologia 2016 December;151(6):587-95
Psoriasis in elderly and non-elderly population: clinical and molecular features
Maddalena NAPOLITANO, Nicola BALATO, Fabio AYALA, Cataldo PATRUNO, Angela PATRÌ, Matteo MEGNA, Anna BALATO ✉
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
BACKGROUND: Psoriasis management in elderly may be difficult, mainly due to comorbidities and concomitant medications. The aim of this study was to compare elderly and non-elderly psoriatic patients in relation to their demographic, clinical and molecular characteristics.
METHODS: A prospective observational study on 502 psoriatic patients attending our outpatient clinic was performed. We analyzed their demographical and clinical features, highlighting differences in comorbidities and treatment adverse events. Moreover, real-time PCR was used to analyze lesional skin expression of CCL-20, HBD-2, Hpt, IFN-α, IL-1β, IL-8, IL-23A, IL-33, IL-36γ, TGF-β, TNF-α, S100A7 and VEGF, in 15 adults and 15 elderly.
RESULTS: The two groups of patients differed for comorbidities and treatment profile. Particularly, non-elderly were treated more frequently with biologic drugs compared to elderly. However, elderly did not develop more metabolic, hepatic and/or renal abnormalities than younger patients. Serious adverse events were comparable between elderly and non-elderly. No difference in gene expression of the investigated mediators was found.
CONCLUSIONS: Our study did not show substantial clinical or molecular differences between elderly and non-elderly. Older patients should be treated with systemic drugs when required. Safety and tolerability profiles of biological drugs seemed at least comparable with those of traditional systemic ones.